Literature DB >> 26140326

Mn(II) mediated degradation of artemisinin based on Fe3O4@MnSiO3-FA nanospheres for cancer therapy in vivo.

Jian Chen1, Weijie Zhang, Min Zhang, Zhen Guo, Haibao Wang, Mengni He, Pengping Xu, Jiajia Zhou, Zhenbang Liu, Qianwang Chen.   

Abstract

Artemisinin (ART) is a natural drug with potent anticancer activities related with Fe(2+) mediated cleavage of the endoperoxide bridge in ART. Herein, we reported that Mn(2+) could substitute for Fe(2+) to react with ART and generate toxic products, inducing a much higher anticancer efficiency. On this basis, we prepared pH-responsive Fe3O4@MnSiO3-FA nanospheres which can efficiently deliver hydrophobic ART into tumors in mice models. Mn(2+) was released in acidic tumor environments and intracellular lysosomes, interacting with ART to kill cancer cells. The ART-loaded nanocarriers could suppress tumor growth more efficiently than free ART, which could be further illustrated by magnetic resonance imaging (MRI). Histological analysis revealed that the drug delivery system had no obvious effect on the major organs of mice. ART has been reported to have lower toxicity than chemotherapeutics. The ART-loaded nanocarriers are promising to be used in improving the survival of chemotherapy patients, providing a novel method for clinical tumor therapy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26140326     DOI: 10.1039/c5nr02402a

Source DB:  PubMed          Journal:  Nanoscale        ISSN: 2040-3364            Impact factor:   7.790


  9 in total

1.  Controllable synthesis Fe3O4@POHABA core-shell nanostructure as high-performance recyclable bifunctional magnetic antimicrobial agent.

Authors:  Zhijia Zhang; Defeng Xing; Xin Zhao; Xiaojun Han
Journal:  Environ Sci Pollut Res Int       Date:  2017-06-28       Impact factor: 4.223

Review 2.  Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy.

Authors:  Zijian Zhou; Jibin Song; Liming Nie; Xiaoyuan Chen
Journal:  Chem Soc Rev       Date:  2016-11-21       Impact factor: 54.564

Review 3.  Manganese-based hollow nanoplatforms for MR imaging-guided cancer therapies.

Authors:  Shuang Liang; Guangfu Liao; Wenzhen Zhu; Li Zhang
Journal:  Biomater Res       Date:  2022-07-06

4.  Poly(norepinephrine)-coated FeOOH nanoparticles as carriers of artemisinin for cancer photothermal-chemical combination therapy.

Authors:  Zi He; Huiling Su; Yuqing Shen; Wei Shi; Xin Liu; Yang Liu; Fuhui Zhang; Yansheng Zhang; Yanan Sun; Dongtao Ge
Journal:  RSC Adv       Date:  2019-03-29       Impact factor: 4.036

5.  Facile total synthesis of lysicamine and the anticancer activities of the RuII, RhIII, MnII and ZnII complexes of lysicamine.

Authors:  Jiao-Lan Qin; Ting Meng; Zhen-Feng Chen; Xiao-Li Xie; Qi-Pin Qin; Xiao-Ju He; Ke-Bin Huang; Hong Liang
Journal:  Oncotarget       Date:  2017-07-26

Review 6.  Smart Responsive Nanoformulation for Targeted Delivery of Active Compounds From Traditional Chinese Medicine.

Authors:  Xuejun Jiang; Mei Lin; Jianwen Huang; Mulan Mo; Houhe Liu; Yuan Jiang; Xiaowen Cai; Wingnang Leung; Chuanshan Xu
Journal:  Front Chem       Date:  2020-12-10       Impact factor: 5.221

Review 7.  Repurposing Artemisinin and its Derivatives as Anticancer Drugs: A Chance or Challenge?

Authors:  Zhaowu Ma; Clariis Yi-Ning Woon; Chen-Guang Liu; Jun-Ting Cheng; Mingliang You; Gautam Sethi; Andrea Li-Ann Wong; Paul Chi-Lui Ho; Daping Zhang; Peishi Ong; Lingzhi Wang; Boon-Cher Goh
Journal:  Front Pharmacol       Date:  2021-12-31       Impact factor: 5.810

Review 8.  Artemisinin-Type Drugs in Tumor Cell Death: Mechanisms, Combination Treatment with Biologics and Nanoparticle Delivery.

Authors:  Xinyu Zhou; Fengzhi Suo; Kristina Haslinger; Wim J Quax
Journal:  Pharmaceutics       Date:  2022-02-10       Impact factor: 6.321

Review 9.  Antitumor Research on Artemisinin and Its Bioactive Derivatives.

Authors:  Yunqin Zhang; Guowei Xu; Shuqun Zhang; Dong Wang; P Saravana Prabha; Zhili Zuo
Journal:  Nat Prod Bioprospect       Date:  2018-04-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.